Gastrointestinal Anastomosis - Market Insights, Competitive Landscape, and Market Forecast - 2032

Gastrointestinal Anastomosis Market by Product Type (Instruments [Stapler, Clips, Rings, and Sutures] and Consumables), Anastomose Type (End-to-End, Side-to-Side, and End-to-Side), Usability (Re-usable and Single-use), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of gastrointestinal disorder and rising product developmental activities in the domain of gastrointestinal anastomosis devices.

The gastrointestinal anastomosis market is estimated to grow at a CAGR of 6.13% during the forecast period from 2025 to 2032. The demand for gastrointestinal anastomosis devices is experiencing steady growth, primarily driven by the increasing prevalence of gastrointestinal disorders such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, and various other forms of gastrointestinal cancers. These conditions often require surgical intervention, including bowel resection, which necessitates the use of anastomosis devices to reconnect segments of the digestive tract. Additionally, the rising number of gastrointestinal surgical procedures performed globally further contributes to the expanding need for effective and reliable anastomosis solutions. These devices play a critical role in ensuring safe reconnections and minimizing postoperative complications. Moreover, the market is witnessing a surge in product development activities aiming at improving surgical outcomes and broadening the application scope of anastomosis tools across open, laparoscopic, and robotic procedures. Together, these factors are laying a strong foundation for sustained and robust growth in the gastrointestinal anastomosis market, with projections indicating significant expansion from 2025 to 2032.

Gastrointestinal Anastomosis Market Dynamics:

As per the study published in The Lancet (2023), the global prevalence of ulcerative colitis reached approximately 5 million cases, with incidence continuing to rise worldwide. Similarly, data from Crohn’s and Colitis UK (2022) reported that 0.81% of the population, or 1 in every 123 people, were living with Crohn’s disease or ulcerative colitis, with the rising cases to 1 in every 67 among individuals over 70 years old in the United Kingdom. In Australia, Crohn’s and Colitis Australia (2022) estimated that 180,000 people were living with inflammatory bowel disease (IBD), including both Crohn’s disease and ulcerative colitis. This increasing global burden of IBD is a major driver for the gastrointestinal anastomosis devices market, as many patients eventually require surgical interventions to manage complications like strictures, perforations, or fistulas. In these procedures, anastomosis devices are essential for safely reconnecting the digestive tract and reducing postoperative complications. Therefore, rising cases of inflammatory bowel disease is driving the growth of the gastrointestinal anastomosis market.

Additionally, the rising prevalence of gastrointestinal cancers is significantly impacting market growth. According to the International Agency for Research on Cancer (2022), there were over 1.1 million new GI cancer cases globally in 2022. Data from the World Cancer Research Fund (2022) reported 1,926,425 new colorectal cancer cases worldwide the same year. Surgical treatment for colorectal and other GI cancers often involves bowel resection followed by anastomosis, reinforcing the demand for advanced surgical devices.

The increasing number of gastrointestinal surgeries is another key growth factor. The National Institutes of Health (2025) reported that 895,606 gastroenterological and abdominal surgical procedures were registered in 2023 in the U.S. National Clinical Database (NCD) alone. Similar trends were being observed in Europe, Asia-Pacific, and other regions, driven by aging populations, cancer prevalence, and access to advanced surgical care. Each of these procedures typically requires precise, leak-resistant anastomosis, boosting the adoption of staplers and other related devices.

To meet this rising demand, major market players are accelerating product innovation. For example, in May 2024, Ethicon (a Johnson & Johnson MedTech company) launched the ECHELON LINEAR™ Cutter, a first-of-its-kind surgical stapler shown to deliver 47% fewer staple-line leaks, helping reduce surgical risks in GI procedures. Such innovations not only improve clinical outcomes but also contribute to stronger market growth.

However, the risk of postoperative complications and high device and procedure costs, among others, are some of the key constraints that may limit the growth of the gastrointestinal anastomosis market.

Gastrointestinal Anastomosis Market Segment Analysis:

Gastrointestinal Anastomosis Market by Product Type (Instruments [Stapler, Clips, Rings, and Sutures] and Consumables), Anastomose Type (End-to-End, Side-to-Side, and End-to-Side), Usability (Re-usable and Single Use), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the gastrointestinal anastomosis market, the stapler category is estimated to account for the largest market share in 2024. This growth of the category is primarily attributed to the rising incidence of gastrointestinal disorders and the clinical, technical, and operational advantages that staplers offer in the surgical management of such conditions. According to The Lancet Europe (2024), over 1.3 million people in Europe were living with inflammatory bowel disease (IBD). Surgical intervention, including bowel resection followed by anastomosis, is a common treatment pathway for severe cases of Crohn’s disease or ulcerative colitis, where staplers play a central role in reconnecting bowel segments.

Staplers have become a mainstay in GI surgery due to their ability to significantly reduce operative time, particularly beneficial in complex or minimally invasive procedures. Their preloaded cartridges, standardized firing mechanisms, and consistent deployment improve procedural efficiency and help reduce the risk of human error. Staplers deliver uniform, precise staple lines, minimizing complications such as anastomotic leaks and dehiscence, especially in high-risk surgeries.

Modern stapling devices, including tissue-sensing systems and tri-staple configurations, adjust staple height and compression to match tissue thickness, thereby optimizing healing outcomes. For example, the ECHELON CIRCULAR™ Powered Stapler from Johnson & Johnson MedTech is specifically designed for secure anastomoses in various configurations, end-to-end, end-to-side, and side-to-side throughout the alimentary tract.

Moreover, market leaders continue to innovate and expand their product portfolios to meet evolving surgical demands. In April 2025, Intuitive Surgical received FDA clearance for its fully wristed SP SureForm 45 Stapler, designed for use with the da Vinci SP robotic surgical system in gastric and colorectal procedures.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of gastrointestinal anastomosis across the globe.

North America is expected to dominate the overall gastrointestinal anastomosis market:

North America is projected to hold the largest share of the gastrointestinal anastomosis market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of gastrointestinal disorders such as inflammatory bowel disease, gastric cancer, and others, a highly advanced healthcare infrastructure, and various product approvals and launches by key market players. Collectively, these factors are positioning North America as the leading market in the global gastrointestinal anastomosis market.

According to data from the Centers for Disease Control and Prevention (2024), the prevalence of inflammatory bowel disease (IBD) in the United States is estimated to range between 2.4 and 3.1 million, with varying burden across population groups. Additionally, the National Institutes of Health (2024) reported that over 1 million people in the U.S. were living with Crohn's disease. Similarly, data from Crohn's and Colitis Canada (2023), in 2023, more than 11,000 adults in Canada were newly diagnosed with Crohn's disease. The rising cases of IBD are driving the need for gastrointestinal surgeries, particularly intestinal resections with anastomosis, thereby fueling the growth of the gastrointestinal anastomosis market in North America.

In addition to IBD, colorectal cancer is a major contributing factor to market expansion. According to the CDC (2025), in 2022, approximately 147,931 colorectal cancer cases were reported in the United States. Furthermore, the American Cancer Society (2025) projected that about 107,320 new cases of colon cancer would be diagnosed in the U.S. in 2025. The increasing burden of colorectal cancer is significantly boosting the demand for surgical resections involving gastrointestinal anastomosis, thus further propelling market growth across the region.

Moreover, technological advancements and product innovation by key industry players are accelerating this growth. For instance, in June 2025, Johnson & Johnson MedTech announced the U.S. launch of the ETHICON™ 4000 Stapler, an advanced surgical stapling device designed to manage tissue complexity and ensure strong staple-line integrity, minimizing the risk of surgical leaks and bleeding during procedures such as gastrectomy.

Collectively, these factors, such as rising gastrointestinal disease cases, product development and launch activities, and robust healthcare infrastructure, are expected to significantly drive the growth of the North America gastrointestinal anastomosis market during the forecast period.

Gastrointestinal Anastomosis Market Key Players:

Some of the key market players operating in the gastrointestinal anastomosis market include Medtronic, NiTi™ Surgical Solutions, Inc., Johnson & Johnson Services, Inc., Smith+Nephew, B. Braun Melsungen AG, Peters Surgical, LeMaitre Vascular, Inc., Baxter, Advanced Medical Solutions Group plc., Microbot Medical, Intuitive Surgical, GT Metabolic Solutions, Inc., Boston Scientific Corporation, Ovesco Endoscopy AG, Seger Surgical Solutions Ltd., Cook, EziSurg Medical Co., Ltd., Lotus Surgicals, Artivion, Inc., Teleflex Incorporated, and others.

Recent Developmental Activities in the Gastrointestinal Anastomosis Market:

• In March 2025, GT Metabolic™ Solutions, Inc. announced that the U.S. FDA had cleared a larger 50mm MagDI™ System magnet, complementing the existing 40mm version. This expansion allows surgeons to treat a wider range of patients using magnet-assisted surgery for duodenal-ileal anastomosis, enhancing procedural flexibility and clinical outcomes.
• In August 2024, Colospan announced that the U.S. FDA granted Breakthrough Device Designation to its CG-100 Intraluminal Bypass Device. This single-use, temporary device is designed for patients with colorectal cancer requiring an anastomosis and typically receiving a protective stoma, offering a less invasive alternative under standard clinical practice.
• In May 2024, Exero Medical launched an international pivotal study to monitor post-gastrointestinal surgery recovery. The study is designed to provide real-time, accurate data on patients’ healing progress, helping personalize care and quickly detect potential life-threatening complications.

Key takeaways from the gastrointestinal anastomosis market report study

• Market size analysis for the current gastrointestinal anastomosis market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the gastrointestinal anastomosis market.
• Various opportunities available for the other competitors in the gastrointestinal anastomosis market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current gastrointestinal anastomosis market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for gastrointestinal anastomosis market growth in the future?

Target audience who can benefit from this gastrointestinal anastomosis market report study

• Gastrointestinal anastomosis product providers
• Research organizations and consulting companies
• Gastrointestinal anastomosis-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in gastrointestinal anastomosis
• Various end-users who want to know more about the gastrointestinal anastomosis market and the latest technological developments in the gastrointestinal anastomosis market.

Frequently Asked Questions for the Gastrointestinal Anastomosis Market:

1. What is gastrointestinal anastomosis?

• Gastrointestinal anastomosis refers to a surgical procedure in which two parts of the gastrointestinal (GI) tract are connected (joined) to restore continuity after a portion has been removed or bypassed. It refers to the use of medical devices such as surgical instruments or tools used to join two sections of the gastrointestinal (GI) tract after part of it has been removed due to disease or injury.

2. What is the market for gastrointestinal anastomosis?

• The gastrointestinal anastomosis market is estimated to grow at a CAGR of 6.13% during the forecast period from 2025 to 2032.

3. What are the drivers for the gastrointestinal anastomosis market?

• The demand for gastrointestinal anastomosis is primarily driven by the rising prevalence of GI disorders such as inflammatory bowel disease, ulcerative colitis, Crohn’s disease, and GI cancers. The increasing number of surgical resections globally necessitates reliable anastomosis to restore digestive continuity. Additionally, ongoing product approval and launches are enhancing surgical outcomes. These factors collectively position the market for steady, robust growth from 2025 to 2032.

4. Who are the key players operating in the gastrointestinal anastomosis market?

• Some of the key market players operating in the gastrointestinal anastomosis market include Medtronic, NiTi™ Surgical Solutions, Inc., Johnson & Johnson Services, Inc., Smith+Nephew, B. Braun Melsungen AG, Peters Surgical, LeMaitre Vascular, Inc., Baxter, Advanced Medical Solutions Group plc, Microbot Medical, Intuitive Surgical, GT Metabolic Solutions, Inc., Boston Scientific Corporation, Ovesco Endoscopy AG, Seger Surgical Solutions Ltd., Cook, EziSurg Medical Co., Ltd., Lotus Surgicals, Artivion, Inc., Teleflex Incorporated, and others.

5. Which region has the highest share in the gastrointestinal anastomosis market?

• North America is projected to hold the largest share of the gastrointestinal anastomosis market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of gastrointestinal disorders such as inflammatory bowel disease, gastric cancer, and others, a highly advanced healthcare infrastructure, and various product approvals and launches by key market players. Collectively, these factors are positioning North America as the leading market in the global gastrointestinal anastomosis market.

This product will be delivered within 2 business days.